Skip to content

    Gufic BioScience

    GUFICBIOMixed
    Healthcare·18 Nov 2024
    Management Summary

    Gufic Biosciences reported a slight decline in Q2 FY25 revenue and PAT year-over-year, primarily attributed to capacity constraints at Navsari and API pricing erosion, with the new Indore facility commencing production only in early October. Despite the short-term challenges, the company is strategically positioning Indore for future growth, focusing on domestic contract manufacturing and eventual entry into regulated markets like the EU and US. Management highlighted progress in various divisions, including critical care, ferticare, aestaderm, neurocare, and international business, while acknowledging the need to manage debtor days.

    Highlights

    9
    • Q2 FY25 Revenue: ₹204.2 crores (down 4.98% YoY)

    • Q2 FY25 EBITDA: ₹38.7 crores (down 2.52% YoY)

    • Q2 FY25 EBITDA Margin: 18.9% (up 43 bps YoY)

    • Q2 FY25 PAT: ₹21.8 crores (down 6.03% YoY)

    • Q2 FY25 PAT Margin: 10.66% (down 14 bps YoY)

    • H1 FY25 Revenue: ₹407 crores (down 0.71% YoY)

    • H1 FY25 EBITDA: ₹79.8 crores (up 4.86% YoY)

    • Indore facility started production on October 3, 2024, with revenue contribution expected from Q3 FY25.

    • EU audit for Indore facility expected June-September 2024, with approval by end of 2025.

    Concerns

    2
    • API Price Erosion from China

    • Capacity Constraints at Navsari Facility

    What Changed3

    vs Q3 FY25

    Tone shiftGood → MixedGuidance items13 → 5 (-8)Risks discussed4 → 3 (-1)
    Key financials

    Metrics

    10

    Periods

    2

    Q2 FY25

    5
    • Revenue
      ₹204.2 Cr
      YoY-5.0%
    • EBITDA
      ₹38.7 Cr
      YoY-2.5%
    • EBITDA Margin
      18.9%
    • PAT
      ₹21.8 Cr
      YoY-6.0%
    • PAT Margin
      10.7%

    H1 FY25

    5
    • Revenue
      ₹407 Cr
      YoY-0.7%
    • EBITDA
      ₹79.8 Cr
      YoY+4.9%
    • EBITDA Margin
      18.6%
    • PAT
      ₹42.6 Cr
      YoY-2.7%
    • PAT Margin
      10.4%

    Guidance & targets

    5
    CategoryTargetPriority
    Capacity
    Indore Facility Potential
    2 to 3 years
    Medium
    Regulatory Approval
    Indore Facility EU Approval
    by end of 2025
    High
    Regulatory Action
    Indore Facility US FDA Action
    calendar year 2026
    Medium
    Business Initiation
    CMO/CDMO Business Initiation
    November and December
    High
    Product Development
    Selvax Project Timeline
    5-year, 6-year window
    Medium

    Risks & concerns

    3
    RiskSeverity

    Increased Debtor Days in Sparsh Division

    Direct credit to hospitals in the Sparsh division leads to an increase in debtor days, though management believes long-term benefits outweigh this short-term challenge.Management acknowledged

    medium

    API Price Erosion from China

    20% of revenue from 6-8 molecules saw 35-50% erosion due to API pricing from China, contributing to revenue stagnation.Management acknowledged

    high

    Capacity Constraints at Navsari Facility

    Navsari facility's capacity limitations prevented meeting market demand, leading to lost revenue in Q2 FY25 before Indore commenced operations.Management acknowledged

    high

    Q&A highlights

    3

    “So, there has been a loss of revenue in the quarter because Indore started in October, October 3 to be precise. So, that's why the capacity which was not available at Navsari could not be met by Indore in the last quarter because the production started in the first week of October.”

    Clarifies the immediate financial impact of the Indore facility's delayed start and its contribution to Q2 FY25 revenue decline.

    asked by Bhavya, Samaasa Capital

    3 min read7 chapters

    Detailed Narrative

    01

    Q2 FY25 Financial Performance Overview

    Gufic Biosciences reported a slight decline in Q2 FY25 standalone revenue to ₹204.2 crores, down 4.98% year-over-year from ₹214.9 crores in Q2 FY24. EBITDA for the quarter was ₹38.7 crores, a 2.52% decrease from ₹39.7 crores last year, though the EBITDA margin improved slightly to 18.9% from 18.47%. Profit after tax (PAT) also saw a decline to ₹21.8 crores, down 6.03% from ₹23.2 crores in the prior year, with PAT margin at 10.66%.

    02

    H1 FY25 Financial Performance Overview

    For the first half of FY25, total revenue stood at ₹407 crores, a marginal decrease of 0.71% compared to ₹409.9 crores in H1 FY24. However, EBITDA for H1 FY25 increased by 4.86% to ₹79.8 crores from ₹76.1 crores in H1 FY24, with EBITDA margin improving to 18.62%. PAT for H1 FY25 was ₹42.6 crores, a 2.74% decline from ₹43.8 crores in H1 FY24, resulting in a PAT margin of 10.44%.

    03

    Indore Facility Commissioning and Strategic Outlook

    The new Indore facility commenced production on October 3, 2024, marking a transformative milestone. Management indicated that revenue contribution from Indore would begin in Q3 FY25, though the 'real potential' is expected to materialize over the next 2-3 years. The short-term strategy involves transferring high-demand products from Navsari to Indore to optimize capacity, allowing Navsari to focus on export orders. Long-term, Indore is positioned for regulated markets, with EU approval targeted by the end of 2025 and US FDA action anticipated in calendar year 2026.

    04

    Challenges Impacting Revenue Stagnation

    Management attributed the stagnant revenue over the past 4-5 quarters to multiple factors, including capacity constraints at the Navsari facility and significant erosion in API pricing. Specifically, 20% of the company's revenue, derived from 6-8 key molecules, experienced a 35-50% erosion due to API price volatility from China. Additionally, a conservative approach was adopted in Q1 and Q2 FY25 to manage the debtor cycle, avoiding excessive credit extension at the cost of revenue.

    05

    Divisional Performance and Pipeline Expansion

    The Critical Care division continues to be a backbone, expanding its pipeline with innovative antifungal and antibacterial molecules and focusing on sepsis management through engagement with over 3,000 healthcare professionals. The Ferticare division is addressing infertility rates by expanding its recombinant hormonal product pipeline and launching specialized task forces. Aesthaderm's STUNNOX is now the second most used botulinum toxin in India, while Neurocare's Zarbot has gained acceptance among 100+ neurologists.

    06

    International Business and Contract Manufacturing

    Gufic's international business is growing through regulated market registrations, having recently secured approvals in Thailand, Sri Lanka, and Lithuania, and winning a UK NHS tender. The Indore facility is expected to support further international expansions. The company is actively pursuing contract manufacturing (CMO/CDMO) opportunities, with audits by domestic and international partners ongoing since May-July, and the CMO/CDMO business expected to be initiated in November-December.

    07

    Selvax Oncology Project Update

    The immune-oncology project, Selvax, targeting solid tumors, has shown promising results in animal studies, including a reported 92% cure rate out of 24 animals in expert studies. While dose determination studies are still pending, the company is working on cell line scalability and large-scale production of anti-CD40 antibodies. Management views Selvax as a 5-6 year window project, emphasizing cautious optimism until further large-scale study data is available.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.